Konruns(SH:603590)2025-04-25 14:55Financial Performance - The company's operating revenue for Q1 2025 was CNY 212,002,399.05, representing a year-on-year increase of 6.41% compared to CNY 199,236,548.72 in the same period last year[4]. - Net profit attributable to shareholders was CNY 44,497,393.80, reflecting a 6.83% increase from CNY 41,654,332.06 in the previous year[4]. - The basic earnings per share (EPS) for the period was CNY 0.28, up 3.70% from CNY 0.27 in the same period last year[4]. - Total operating revenue for Q1 2025 reached ¥212,002,399.05, an increase of 6.9% compared to ¥199,236,548.72 in Q1 2024[21]. - Net profit for Q1 2025 was ¥48,137,550.37, compared to ¥46,845,096.86 in Q1 2024, representing an increase of 2.8%[21]. - The company's gross profit margin improved to approximately 77.5% in Q1 2025 from 76.8% in Q1 2024[21]. - Basic earnings per share for Q1 2025 were ¥0.28, compared to ¥0.27 in Q1 2024, indicating a slight increase[22]. Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 31,512,207.33, a significant decrease of 169.98% compared to a positive cash flow of CNY 45,031,453.62 in the previous year[4][7]. - In Q1 2025, the net cash flow from operating activities was -$31.51 million, a significant decline from $45.03 million in Q1 2024, representing a year-over-year decrease of 170%[26]. - Cash inflow from operating activities totaled $175.70 million in Q1 2025, down 21.4% from $223.45 million in Q1 2024[26]. - The company reported cash outflows from operating activities of $207.22 million in Q1 2025, an increase of 16.2% compared to $178.42 million in Q1 2024[26]. - The ending balance of cash and cash equivalents was $212.13 million in Q1 2025, down from $311.22 million in Q1 2024, a decrease of 31.9%[27]. - The company’s cash and cash equivalents increased by $22.15 million in Q1 2025, compared to an increase of $83.99 million in Q1 2024, indicating a decline of 73.6%[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,885,168,355.02, a decrease of 0.88% from CNY 3,919,688,890.45 at the end of the previous year[5]. - Total liabilities decreased to ¥445,504,171.41 from ¥493,524,893.69, a decline of 9.8%[18]. - The equity attributable to shareholders was CNY 3,154,272,355.95, showing a slight increase of 0.31% from CNY 3,144,412,325.67 at the end of the previous year[5]. - The company's equity attributable to shareholders increased to ¥3,154,272,355.95 from ¥3,144,412,325.67, a growth of 0.3%[18]. Research and Development - The company has completed the Phase III clinical trial for the innovative traditional Chinese medicine ZY5301, which targets chronic pelvic pain, and has submitted the new drug application for regulatory review[12]. - The KC1036 project has enrolled over 300 participants in clinical studies, demonstrating significant anti-tumor activity and good safety profiles, supporting its use in treating adolescent solid tumors[13]. - The KC1086 project has received clinical trial approval, aimed at treating advanced recurrent or metastatic solid tumors, marking a significant milestone for the company's R&D efforts[14]. - The company is actively communicating with regulatory authorities regarding the ZY5301 drug registration application, indicating a proactive approach to market entry[12]. Shareholder Information - The company had a total of 11,180 common shareholders at the end of the reporting period[9]. - The largest shareholder, Liu Jianhua, held 31.87% of the shares, amounting to 50,786,760 shares, with 8,846,840 shares pledged[9]. - The company has not reported any changes in the shareholding structure of the top 10 shareholders due to securities lending activities[11]. Other Financial Metrics - Non-recurring gains and losses for the period totaled CNY 597,771.28 after accounting for tax effects and minority interests[7]. - Research and development expenses decreased to ¥8,078,499.71 in Q1 2025 from ¥11,319,522.81 in Q1 2024, a reduction of 28.5%[21]. - Other comprehensive income for Q1 2025 showed a significant loss of ¥38,283,346.86, contrasting with a gain of ¥38,109,331.65 in Q1 2024[22]. - Cash flow from investing activities generated a net inflow of $38.64 million in Q1 2025, compared to $14.50 million in Q1 2024, marking a year-over-year increase of 166.5%[27].